Currently, there are several clinical trials involving FDA-approved immunosuppressive checkpoint inhibitors, which attack tumor cells expressing PD-L1 by blocking the PD-L1/PD-1 signaling pathway, so as to improve the treatment and prognosis of patients. The gene discussed is CD274; the disease is neoplasm.